|
|
||||||||
CLINICAL STUDY |
1 Institute of Clinical Psychology and Psychotherapy, Technical University of Dresden, Germany, 2 Internal Medicine/Endocrinology and Clinical Chemistry, Max Planck Institute of Psychiatry, Kraepelinstr. 10, 80804 Munich, Germany, 3 Pfizer GmbH, Karlsruhe, Germany and 4 Institute of Clinical Chemistry, Medical University, Graz, Austria
(Correspondence should be addressed to H J Schneider; Email: schneider{at}mpipsykl.mpg.de)
Objective: Insulin-like growth factor-I (IGF-I) has been suggested to be a prognostic marker for the development of cancer and, more recently, cardiovascular disease. These diseases are closely linked to obesity, but reports of the association of IGF-I with measures of obesity are divergent. In this study, we assessed the association of age-dependent IGF-I standard deviation scores with body mass index (BMI) and intra-abdominal fat accumulation in a large population.
Design: A cross-sectional, epidemiological study.
Methods: IGF-I levels were measured with an automated chemiluminescence assay system in 6282 patients from the DETECT study. Weight, height, and waist and hip circumference were measured according to the written instructions. Standard deviation scores (SDS), correcting IGF-I levels for age, were calculated and were used for further analyses.
Results: An inverse U-shaped association of IGF-I SDS with BMI, waist circumference, and the ratio of waist circumference to height was found. BMI was positively associated with IGF-I SDS in normal weight subjects, and negatively associated in obese subjects. The highest mean IGF-I SDS were seen at a BMI of 22.525 kg/m2 in men (+0.08), and at a BMI of 27.530 kg/m2 in women (+0.21). Multiple linear regression models, controlling for different diseases, medications and risk conditions, revealed a significant negative association of BMI with IGF-I SDS. BMI contributed most to the additional explained variance to the other health conditions.
Conclusions: IGF-I standard deviation scores are decreased in obesity and underweight subjects. These interactions should be taken into account when analyzing the association of IGF-I with diseases and risk conditions.
This article has been cited by other articles:
![]() |
H. Jorn Schneider, J. Klotsche, B. Saller, S. Bohler, C. Sievers, D. Pittrow, G. Ruf, W. Marz, W. Erwa, A. M Zeiher, et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients Eur. J. Endocrinol., February 1, 2008; 158(2): 153 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Brabant, A. Krogh Rasmussen, B. M. K. Biller, M. Buchfelder, U. Feldt-Rasmussen, K. Forssmann, B. Jonsson, M. Koltowska-Haggstrom, D. Maiter, B. Saller, et al. Clinical Implications of Residual Growth Hormone (GH) Response to Provocative Testing in Adults with Severe GH Deficiency J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2604 - 2609. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |